Literature DB >> 22370802

[Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa].

A Rubbert-Roth1.   

Abstract

The term orphan disease is used for those diseases which are diagnosed in less than 5 out of 10,000 persons. An example of an orphan disease in rheumatology is panarteritis nodosa (PAN), the clinical manifestation of which ranges from mild forms to life-threatening situations. The scientific publications on the diagnosis and therapy of PAN are usually limited to casuistics and small case studies. Treatment of this disease is usually carried out analogue to other forms of vasculitis but the therapeutics used are not formally approved for PAN. With this in mind it is much more realistic to treat such patients in specialized centers or at least to allow an evidence-based medical treatment in, for example network associations, using the targeted documentation of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370802     DOI: 10.1007/s00393-011-0902-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  7 in total

1.  Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa.

Authors:  M Kroiss; U Hohenleutner; C Gruss; A Glaessl; M Landthaler; W Stolz
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

2.  EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.

Authors:  S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

3.  Classification and epidemiology of systemic vasculitis.

Authors:  D G Scott; R A Watts
Journal:  Br J Rheumatol       Date:  1994-10

4.  Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.

Authors:  Loïc Guillevin; Alfred Mahr; Patrice Callard; Pascal Godmer; Christian Pagnoux; Emmanuelle Leray; Pascal Cohen
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

5.  Infliximab in a child with therapy-resistant systemic vasculitis.

Authors:  Sandra W K de Kort; Marion A J van Rossum; Rebecca ten Cate
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

6.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.

Authors:  Loïc Guillevin; Pascal Cohen; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Xavier Puéchal; Edouard Pertuiset; Brigitte Gilson; Mohamed Hamidou; Patricia Lanoux; Alain Bruet; Marc Ruivard; Philippe Vanhille; Jean-François Cordier
Journal:  Arthritis Rheum       Date:  2003-02-15

7.  The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa.

Authors:  R W Lightfoot; B A Michel; D A Bloch; G G Hunder; N J Zvaifler; D J McShane; W P Arend; L H Calabrese; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.